Breadcrumb

  • INVESTORS /
  • PRESS RELEASES /
  • Exicure to Present at TIDES 2019 on Preclinical and Clinical Development of AST-008

PRESS RELEASE

Printer Friendly Version View printer-friendly version
<< Back
Exicure to Present at TIDES 2019 on Preclinical and Clinical Development of AST-008

CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 22, 2019-- Exicure, Inc. (OTCQB: XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, announced a presentation at TIDES: Oligonucleotide and Peptide Therapeutics, the world’s largest meeting to accelerate oligonucleotide and peptide products from early discovery to late-stage development and commercialization.

The talk, “Preclinical and Clinical Development of AST-008, A Toll-like Receptor Agonist 9 Spherical Nucleic Acid for Immuno-oncology Applications,” will be presented by Weston Daniel, Exicure Senior Director of Program Management, at the conference, May 20-23 at Manchester Grand Hyatt in San Diego.

Presentation Date/Time:Wednesday, May 22, 12:45 – 4:35 p.m. PT
Room: Seaport A
Session: Oligonucleotide Discovery, Preclinical and Clinical

About Exicure, Inc.

Exicure, Inc. is a clinical-stage biotechnology company developing therapeutics for immuno-oncology, inflammatory diseases and genetic disorders based on our proprietary Spherical Nucleic Acid, or SNA technology. We believe Exicure's proprietary SNA™ architecture has distinct chemical and biological properties that may provide advantages over other nucleic acid therapeutics and may have therapeutic potential to target diseases not typically addressed with other nucleic acid therapeutics. Exicure's lead program is in a Phase1b/2 trial in patients with advanced solid tumors. Exicure is based outside of Chicago, IL.www.exicuretx.com

Source: Exicure, Inc.

MacDougall
Karen Sharma
781-235-3060
ksharma@macbiocom.com


Print Page  | RSS Feeds  | E-mail Alerts  | IR Contacts